We are pleased to announce the 2023 InfuCare Rx® Scholarship Program recipients! We proudly congratulate the following students: Caitlin Sorrell, Luc Chapall, Kyle Rowton, Tanisha Armstrong, Jack Law, and Elliott Janis. The annual InfuCare Rx Scholarship Program offers three categories: bleeding disorders, neuromuscular conditions, and primary immunodeficiencies. Our program offers financial support for individuals diagnosed with these chronic conditions and pursuing higher education to expand their careers and better their futures. With each passing year, we receive a significant number of qualified individuals, which makes the decision process tremendously difficult. The individuals who apply bravely battle their health challenges while dedicating time and effort to their studies. Ultimately, the students selected stood out as people who symbolize determination, courage, and the willpower to never let their condition stop them from their dreams!
Today InfuCare Rx, a leading national specialty infusion therapy provider, announced the completion of their acquisition of the business assets of Health First Infusion (HFI), a licensed home infusion pharmacy located in Florida. “The HFI asset acquisition is part of a multi-faceted plan to expand into new regions and pursue our mission of providing high-quality, cost-effective care to patients with acute and chronic health conditions,” said Deven Patel, founder and CEO of InfuCare Rx.
We are pleased to announce the 2022 InfuCare Rx Scholarship Program recipients! Congratulations to the following students: MacKale McGuire, Luke Luckey, Chelsie Anjo, Matthew Asch, Kelsie Cox, and Maisie Richardson. At InfuCare Rx, we offer scholarships in three categories: bleeding disorders, primary immunodeficiencies, and neuromuscular conditions. Our annual scholarship program offers the financial support for individuals who are diagnosed with these chronic conditions and are pursuing a higher education to better themselves, their futures, and the lives of those around them. Each year we receive a significant and growing number of qualified applicants, making the decision process increasingly difficult. The individuals who apply boldly battle their own daily challenges, while dedicating time and effort to furthering their education.
NEW YORK – One Equity Partners (“OEP”), a middle market private equity firm, today announced that it has completed a strategic investment of InfuCare Rx (or “the Company”), a national provider of specialty infusion therapies and comprehensive clinical therapy management services to patients with complex conditions. Financial terms of the private transaction were not disclosed.
InfuCare Rx is pleased to announce its selection as a limited distribution provider of VYVGART™. VVGART™ has been approved by the Food & Drug Administration (FDA) in the treatment of generalized myasthenia gravis (gMG) in adults who test positive for the antiacetylcholine receptor (AChR) antibody. InfuCare Rx is a leading data-driven nationwide specialty infusion provider. […]